| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5647116 | Journal of Allergy and Clinical Immunology | 2017 | 56 Pages |
Abstract
BT is a treatment option in patients with severe therapy-refractory asthma that downregulates selectively structural abnormalities involved in airway narrowing and bronchial reactivity, particularly ASM, neuroendocrine epithelial cells, and bronchial nerve endings.
Keywords
Subepithelial basement membraneACTASMFVCSBMIQROCsPGPAQLQrefractory asthmaBronchial epitheliumAirway remodelingintensive care unitICUBronchial thermoplastyAsthma control testforced vital capacityAirway smooth muscleinterquartile rangeAsthma Quality of Life Questionnaireprotein gene productAsthma controloral corticosteroid
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Marina PharmD, PhD, Anders PhD, Gabriel MD, PhD, Marie-Christine MD, Dominique MS, Fatima MS, Loubna MD, Camille MD, PhD, Pascal MD, PhD, Jonas S. PhD, Michel MD,